BR112022000523A2 - Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica - Google Patents
Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêuticaInfo
- Publication number
- BR112022000523A2 BR112022000523A2 BR112022000523A BR112022000523A BR112022000523A2 BR 112022000523 A2 BR112022000523 A2 BR 112022000523A2 BR 112022000523 A BR112022000523 A BR 112022000523A BR 112022000523 A BR112022000523 A BR 112022000523A BR 112022000523 A2 BR112022000523 A2 BR 112022000523A2
- Authority
- BR
- Brazil
- Prior art keywords
- polymorph
- treating
- disease
- methods
- inhibiting
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000002235 sarcomere Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875355P | 2019-07-17 | 2019-07-17 | |
| PCT/US2020/042390 WO2021011809A1 (en) | 2019-07-17 | 2020-07-16 | Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022000523A2 true BR112022000523A2 (pt) | 2022-03-03 |
Family
ID=71995105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000523A BR112022000523A2 (pt) | 2019-07-17 | 2020-07-16 | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220274969A1 (https=) |
| EP (1) | EP3999181B1 (https=) |
| JP (1) | JP2022542803A (https=) |
| KR (1) | KR20220082803A (https=) |
| CN (1) | CN114667283B (https=) |
| AU (1) | AU2020315433A1 (https=) |
| BR (1) | BR112022000523A2 (https=) |
| CA (1) | CA3144974A1 (https=) |
| CL (1) | CL2022000089A1 (https=) |
| ES (1) | ES2982707T3 (https=) |
| IL (1) | IL289881A (https=) |
| MX (1) | MX2022000498A (https=) |
| NZ (1) | NZ784931A (https=) |
| PH (1) | PH12022550084A1 (https=) |
| TW (1) | TW202116764A (https=) |
| WO (1) | WO2021011809A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE552236T1 (de) * | 2003-01-14 | 2012-04-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz |
| WO2007078815A2 (en) * | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2019144041A1 (en) * | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
-
2020
- 2020-07-16 BR BR112022000523A patent/BR112022000523A2/pt unknown
- 2020-07-16 PH PH1/2022/550084A patent/PH12022550084A1/en unknown
- 2020-07-16 NZ NZ784931A patent/NZ784931A/en unknown
- 2020-07-16 MX MX2022000498A patent/MX2022000498A/es unknown
- 2020-07-16 JP JP2022502217A patent/JP2022542803A/ja active Pending
- 2020-07-16 CA CA3144974A patent/CA3144974A1/en active Pending
- 2020-07-16 ES ES20753564T patent/ES2982707T3/es active Active
- 2020-07-16 TW TW109124109A patent/TW202116764A/zh unknown
- 2020-07-16 WO PCT/US2020/042390 patent/WO2021011809A1/en not_active Ceased
- 2020-07-16 AU AU2020315433A patent/AU2020315433A1/en not_active Abandoned
- 2020-07-16 EP EP20753564.2A patent/EP3999181B1/en active Active
- 2020-07-16 US US17/627,590 patent/US20220274969A1/en active Pending
- 2020-07-16 KR KR1020227002979A patent/KR20220082803A/ko not_active Ceased
- 2020-07-16 CN CN202080059957.7A patent/CN114667283B/zh active Active
-
2022
- 2022-01-12 CL CL2022000089A patent/CL2022000089A1/es unknown
- 2022-01-16 IL IL289881A patent/IL289881A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220274969A1 (en) | 2022-09-01 |
| IL289881A (en) | 2022-03-01 |
| EP3999181B1 (en) | 2024-05-29 |
| CN114667283B (zh) | 2023-12-26 |
| CN114667283A (zh) | 2022-06-24 |
| KR20220082803A (ko) | 2022-06-17 |
| AU2020315433A1 (en) | 2022-03-03 |
| JP2022542803A (ja) | 2022-10-07 |
| NZ784931A (en) | 2025-03-28 |
| PH12022550084A1 (en) | 2023-04-12 |
| ES2982707T3 (es) | 2024-10-17 |
| CA3144974A1 (en) | 2021-01-21 |
| EP3999181A1 (en) | 2022-05-25 |
| TW202116764A (zh) | 2021-05-01 |
| MX2022000498A (es) | 2022-02-03 |
| EP3999181C0 (en) | 2024-05-29 |
| WO2021011809A1 (en) | 2021-01-21 |
| CL2022000089A1 (es) | 2022-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022000494A2 (pt) | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica | |
| BR112022000523A2 (pt) | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica | |
| BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
| BR112021020682A2 (pt) | Derivados de 1,3,4-oxadiazol como inibidores de histona deacetilase | |
| IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
| US20210139456A1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| MX2018001193A (es) | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| DOP2020000037A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| MA52967B1 (fr) | Composés antagonistes du pcsk9 | |
| BR112021015238A2 (pt) | Novos anticorpos de ligação a cd40 | |
| UA119147C2 (uk) | Сульфонаміди як модулятори натрієвих каналів | |
| PH12022550083A1 (en) | Cardiac sarcomere inhibitor oral formulations | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| BR112018075206A2 (pt) | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| EP4631505A3 (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| BR112018069930A2 (pt) | agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos | |
| EA201890448A1 (ru) | Фумагиллиновые спироциклические соединения и конденсированные бициклические соединения и способы их получения и применения | |
| PL3956326T3 (pl) | Pochodne (r)-3-(3-chloro-5-fluoro-2-((4-(1h-pirazol-1-ilo)-2-metylochinolin-8-yloksy)metylo)fenylo)morfoliny i związki pokrewne jako antagonista receptora bradykininy (bk) b2 do leczenia chorób skóry | |
| EA201892460A1 (ru) | Производные аденина как ингибиторы протеинкиназ | |
| MX2020013729A (es) | Compuestos de cianotriazol y usos de los mismos. | |
| BR112022000474A2 (pt) | Formas polimórficas de (r)-4-(1-((3-(difluorometil)-1-metil-1h-pirazol-4-il)sulfonil)-1-fluoroetil)-n-(isoxazol-3-il)piperidina-1-carboxamida | |
| EA201892687A1 (ru) | Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение | |
| MX2021014918A (es) | Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |